SABS - SAB Bio jumps 19% after SAB-185 retains neutralization against Omicron variant

SAB Biotherapeutics (NASDAQ:SABS) soars 19% premarket after announcing data, demonstrating that SAB-185, a therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The results indicate that SAB-185 retains a potent ability to neutralize recombinant S protein lentiviral pseudovirus that mimics the SARS-CoV-2 Omicron (B.1.1.529) variant. Although SAB-185 retained potent neutralization of the Omicron variant, it did show a mild-moderate reduction in potency compared to the wild type. Additional analyses are ongoing.

For further details see:

SAB Bio jumps 19% after SAB-185 retains neutralization against Omicron variant